The Roles of Interleukin-27 in Tumor Immunity

Total Page:16

File Type:pdf, Size:1020Kb

The Roles of Interleukin-27 in Tumor Immunity The Roles of Interleukin-27 in Tumor Immunity DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Zhenzhen Liu Program: Ohio State Biochemistry Program (OSBP) * * * * * The Ohio State University 2012 Dissertation Committee: Professor Xue-Feng Bai, Advisor Professor Lai-Chu Wu, Co-advisor Professor Pravin Kaumaya Professor Qianben Wang i ii Abstract Interleukin-27 (IL-27) is a member of the IL-12 family of cytokines. IL-27 is a heterodimer consisting of an IL-12 p40-related protein subunit, EBV-induced gene 3 (EBI3) and a p35-related subunit, p28. IL-27 is mainly produced by activated antigen presenting cells. It functions through engaging IL-27 receptor, which is expressed on a variety of immune cell types, including CD4+ and CD8+ T cells. Overexpression of IL-27 by tumor cells exerts potent anti-tumor activity through diverse mechanisms, in which CD8+ T cells were considered to be the main effector cells. However, the exact mechanisms by which IL-27 enhances anti-tumor CD8+ T cell response and leads to tumor rejection remain unclear. The impacts of IL-27 on the differentiation and activation of CD8+ T cells were studied by stimulating naïve tumor antigen-specific CD8+ T cells (P1CTL) with cognate P1A peptide in the presence and absence of IL-27. First, T cell proliferation and apoptosis were examined by thymidine incorporation and Annexin V/7-AAD staining, respectively. Second, expressions of activation and differentiation markers of T cells were analyzed by Real time PCR and Western Blotting. Third, cytokine production was evaluated by ELISA and flow cytometry. To investigate the in vivo roles of IL-27 in tumor immunity, mouse models involving tumor cells (J558 plasmacytoma and B16 melanoma) expressing IL-27 and IL-27-deficient (EBI3-/-) mice were used. To delineate the mechanisms by ii which IL-27 enhances antitumor CTL responses, tumor antigen specific CD8+ T cells were adoptively transferred into various genetically engineered mice with established tumors, and their in vivo proliferation and apoptosis were studied by CSFE staining and flow cytometry analysis. To examine the role of IL-27 in response and function of T regulatory cells, Anti-CD25 antibody was used to deplete Treg cells; IL-27 deficient or WT CD4+CD25+ Treg cells were adoptively transferred together with effector T cells into tumor-bearing mice; tumor establishment and metastases were evaluated by monitoring s.c. tumor growth and weighing lungs, respectively. Overall, we have uncovered four novel findings that can explain why IL-27 boosts antitumor CD8+ T cell responses: 1) IL-27 enhances the survival of activated tumor antigen specific CD8+ T cells both in vitro and in vivo. 2) IL-27 induces a unique memory precursor cell (MPC) phenotype in activated tumor antigen specific CD8+ T cells, which is characterized by up-regulation of SOCS3, Bcl-6, Sca-1 and IL-10. 3) IL-27 robustly induces IL-10 production by tumor antigen specific CD8+ T cells, which contributes to IL-27-mediated tumor rejection in vivo. 4) IL-27 inhibits the expansion and immunesuppressive ability of CD4+FoxP3+ T regulatory cells, resulting in more potent anti-tumor CTL responses. iii Our findings suggest that: 1) IL-27 has the potential to be used as an adjuvant to boost the efficacy of antitumor vaccines; 2) IL-27 can be used to culture tumor antigen-specific CTLs for adoptive transfer therapy of cancer patients. iv Dedication To my Parents, Lierong Chen and Xiancheng Liu, who gave me life, taught me to be independent and grateful, and support me to pursuit my dreams. To my Advisor, Dr. Xue-Feng Bai, who gave me the chance to continue my Ph.D. study in the U.S., brought me into the exciting world of tumor immunology, and taught me how to employ the power of immunology to do cancer research. His unconditional support, enthusiasm, and encouragement have been instrumental to the success of this project. His style of decision-making, problem-solving and taking responsibility for his students will also serve as my role model for my future career. To my Boyfriend, Andreas Schick, who has been my rock, who has kept me going and always been positive and encouraging through the rough patches and the good ones as well. v Acknowledgments It is with sincerest gratitude that I would like to acknowledge the following people who have been instrumental in helping me to achieve my goal of Ph.D. Dr. Jin-Qing Liu, for her assistance with experiments and sharing her experience. Dr. Lai-Chu Wu, a special thank to you. For your support, your encouragement, and for truly being there for me. Dr. Fatemeh Talebian, my lab partner, for her friendship, lively discussions, and assistance with experiments and training. It was a much better journey since we were able to share it. Dr. Pravin Kaumaya, for everything you have done for me. Thank you for believing in me when I was going through that tough time. Dr. Qianben Wang, for all your support and understanding, for the knowledge and encouragement for making a better future for myself. I am deeply grateful and appreciative for making me open my mind to my future capacity. Dr. Shulin Li, for his generousness providing me with Ad-IL-27, for his guidance on my Ph.D. study, and for his unhesitant sharing life experience with me. Dr. Kevin Foy and Megan Miller, for their helps and kindness that walked me through the darkness. I will always remember the time we were together in Dr. Kaumaya’s lab. Dr. Zhong Chen and Dr. Wen Yi, for their academic comments and suggestions on my Ph.D. research, for I might not have gone the distance without your guys support. Dr. Ying An and Dr. Li Ma, for their support and friendship that carried me through some tough times. It would have been much more difficult without them. I reserve my deepest appreciation and gratitude to my family, friends and loved ones who gave their unlimited stores of love and support. Thank them for reminding me “I Can Do It”. Last but certainly not least, I thank my mother and father, Lierong and Xiancheng, for everything they have given me, all they have done for me, and all they still do. Thank them for all the meaning they have infused into my life and all that they keep on giving. vi VITA Born: May 14th, 1983 Shiyan, Hubei Province, China 2001-2005: China Agriculture University, Beijing, China College of Animal Science and Technology Bachelor’s of Science Major: Animal Science and Technology 2005-2007: China Agriculture University, Beijing, China Department of Animal Genetics and Reproduction Master’s of Science Major: Animal Genetics 2007-2010: The Ohio State University, Columbus, Ohio USA Ohio State Biochemistry Program Master’s of Science Major: Biochemistry 2007-2012: The Ohio State University, Columbus, Ohio USA Department of Pathology Doctor of Philosophy Fields of Study: Cancer Immunology, Molecular and Cellular biology vii RESEARCH EXPERIENCE Research Lab Work Experience The Ohio State University, Department of Pathology/OBGYN Columbus, OH Graduate Research Associate in Cancer Immunology 2008 – Present Project 1: The roles of Interleukin-27 in tumor immunity Generated IL-27-overexpression tumor cell lines Conducted a variety of immuno-based and biochemical in vitro assays to test the effects of IL- 27 in the differentiation and function of tumor specific CD8+ cells Performed adoptive transfer of tumor specific CD8+ T cells to tumor bearing mice Analyzed the IL-27-induced immune responses to established local plasmacytoma (J558) and metastatic melanoma (B16) on various transgenic mouse models. Investigated the mechanisms by which IL-27 enhances antitumor CTL responses and leads to tumor regression Project 2: The interaction of CD200-CD200R in tumor immunity Examined CD200/CD200R expression on myeloid cells and T cells under various conditions Studied the impact of tumor expression of CD200 on tumor formation and metastasis, using the CD200-positive tumor cells, various transgenic mouse models, in vivo cell depletion, and adoptive cell therapy Discovered that high CD200 expression on human cancer cells may lead to long survival time through analyzing microarray data Project 3: Th17 and Treg responses in EBI3-deficient mice Characterized the dynamic changes of CD4+ T cell subsets in EBI3-/- mice with EAE disease Conducted in vitro and in vivo T cell proliferation assay to evaluate the suppressive effect of EBI3-/- Treg Project 4: Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti- angiogenesis responses Designed and synthesized novel peptide mimics: HER2 and VEGF Evaluated the efficacy of the two peptide mimics as a combination treatment for breast cancer both in vitro and in vivo. China Agriculture University, Department of Animal Genetics Beijing, China Graduate Research Associate in Animal Genetics and Reproduction 2004 – 2007 Project 1: Molecular Mechanism of Chromium in Promoting Chicken Growth In order to understand the molecular mechanism by which chromium enhances the action of insulin and subsequently promotes chicken growth, I examined carcass traits, insulin and glucose in the serum, and mRNA expression of genes in the insulin signaling pathway, such as insulin, IR, IRS and IGF-1. Project 2: Sex-reversed Chickens Induced by Aromatase Inhibitor The purpose of this study is to understand the mechanism of avian sex determination and differentiation. Female chicken treated with aromatase inhibitor can ejaculate fully fertile spermatozoa. In addition, W sperms are present in sex-reversed chicken and they are able to reproduce healthy baby chickens. Project 3: Analysis of SNP Markers for Blue-shelled Gene in Chicken by PCR-SSCP In order to understand the cause of eggshell pigmentation biosynthesis, a bioinformatics approach was first used to blast the genes for enzymes involved in porphyrin pathway.
Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
    [Show full text]
  • A1068-CD86 Polyclonal Antibody
    BioVision 05/16 For research use only CD86 Polyclonal Antibody CATALOG NO: A1068-100 ALTERNATIVE NAMES: T-lymphocyte activation antigen CD86, Activation B7-2 antigen, B70, BU63, CTLA-4 counter-receptor B72, FUN-1, CD86, CD86, CD28LG2 Western blot analysis of CD86 in NCI-H292 cell line lysate AMOUNT: 100 µl IMMUNOGEN: KLH conjugated synthetic peptide between 269-298 amino acids from the C-terminal region of human CD86. MOLECULAR WEIGHT: 37 kDa HOST/ISOTYPE: Rabbit IgG SPECIES REACTIVITY: Human PURIFICATION: This antibody is purified through a protein A column, followed by peptide affinity purification. FORM: Liquid FORMULATION: Supplied in PBS with 0.09% (W/V) sodium azide. STORAGE CONDITIONS: Maintain refrigerated at 2-8°C for up to 6 months. For long term RELATED PRODUCTS storage store at -20°C in small aliquots to prevent freeze-thaw cycles. DESCRIPTION: This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by Human CellExp™ B7-2 /CD86, human recombinant (Cat. No. 7496-10, -50) antigen-presenting cells, and it is the ligand for two proteins at the CD86 (Human) ELISA Kit (Cat. No. K4175-100) cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte- Human CellExp™LAG3 /CD223, human recombinant (Cat. No. 7278-10, -50) associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this CD223 (LAG3) Polyclonal Antibody (Cat. No. A1067-100) protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response.
    [Show full text]
  • Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
    Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples Qiang Liu Chinese Academy of Medical Sciences & Peking Union Medical College Yihang Qi ( [email protected] ) Chinese Academy of Medical Sciences and Peking Union Medical College https://orcid.org/0000-0001- 7589-0333 Jie Zhai Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyi Kong Chinese Academy of Medical Sciences & Peking Union Medical College Xiangyu Wang Chinese Academy of Medical Sciences & Peking Union Medical College Yi Fang Chinese Academy of Medical Sciences & Peking Union Medical College Jing Wang Chinese Academy of Medical Sciences & Peking Union Medical College Research Keywords: Cancer immunotherapy, CD223, LAG3, Immune response, Inammatory activity Posted Date: June 19th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-36422/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/33 Abstract Background Despite the promising impact of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a large number of cancer patients fail to respond. LAG3 (Lymphocyte Activating 3), also named CD233, is a protein Coding gene served as alternative inhibitory receptors to be targeted in the clinic. The impact of LAG3 on immune cell populations and co-regulation of immune response in breast cancer remained largely unknown. Methods To characterize the role of LAG3 in breast cancer, we investigated transcriptome data and associated clinical information derived from a total of 2994 breast cancer patients. Results We observed that LAG3 was closely correlated with major molecular and clinical characteristics, and was more likely to be enriched in higher malignant subtype, suggesting LAG3 was a potential biomarker of triple-negative breast cancer.
    [Show full text]
  • Supplemental Table S1
    Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1
    [Show full text]
  • Diabetes in the Absence of LAG-3 Cutting Edge
    Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3 Maria Bettini, Andrea L. Szymczak-Workman, Karen Forbes, Ashley H. Castellaw, Mark Selby, Xiaoyu Pan, This information is current as Charles G. Drake, Alan J. Korman and Dario A. A. Vignali of September 24, 2021. J Immunol 2011; 187:3493-3498; Prepublished online 26 August 2011; doi: 10.4049/jimmunol.1100714 http://www.jimmunol.org/content/187/7/3493 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2011/08/26/jimmunol.110071 Material 4.DC1 http://www.jimmunol.org/ References This article cites 25 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/187/7/3493.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3 Maria Bettini,* Andrea L.
    [Show full text]
  • Point Mutation in CD19 Facilitates Immune Escape of B Cell Lymphoma from CAR-­T Cell Therapy
    Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-001150 on 6 October 2020. Downloaded from Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR- T cell therapy 1 1 1 1 1 1 Zhen Zhang, Xinfeng Chen, Yonggui Tian, Feng Li , Xuan Zhao, Jinyan Liu, 1 1,2,3,4 Chang Yao, Yi Zhang To cite: Zhang Z, Chen X, ABSTRACT relapses after CD19 CAR-T cell therapy are Tian Y, et al. Point mutation Background Tumor relapse due to mutation in CD19 can attributed to the antigen loss, indicating an in CD19 facilitates immune hinder the efficacy of chimeric antigen receptor (CAR)- T urgent need for investigating the mechanisms escape of B cell lymphoma from cell therapy. Herein, we focused on lymphoma patients CAR- T cell therapy. Journal underlying recurrence and for improving whose B cells exhibited a point mutation in CD19 of B cells 4 5 for ImmunoTherapy of Cancer the efficacy of CAR- T cell therapy. Inter- 2020; :e001150. doi:10.1136/ after CAR-T cell infusion. 8 + estingly, one of the specific mechanisms jitc-2020-001150 Methods The CAR- T and CD19 B cells from peripheral blood or bone marrow were assessed using flow of tumor escape that has been reported cytometry. Genome sequencing was conducted to identify suggests that exon mutations affecting the ► Additional material is + published online only. To view, the molecular characteristics of CAR- T and CD19 B cells CD19 gene and its splicing isoforms, leading please visit the journal online from pre-rela pse and postrelapse samples.
    [Show full text]
  • LAG-3: from Molecular Functions to Clinical Applications
    Open access Review J Immunother Cancer: first published as 10.1136/jitc-2020-001014 on 13 September 2020. Downloaded from LAG-3: from molecular functions to clinical applications Takumi Maruhashi , Daisuke Sugiura , Il- mi Okazaki , Taku Okazaki To cite: Maruhashi T, Sugiura D, ABSTRACT (PD-1) and cytotoxic T lymphocyte antigen Okazaki I, et al. LAG-3: from To prevent the destruction of tissues owing to excessive 4 (CTLA-4) significantly improved the molecular functions to clinical and/or inappropriate immune responses, immune outcomes of patients with diverse cancer applications. Journal for cells are under strict check by various regulatory ImmunoTherapy of Cancer types, revolutionizing cancer treatment. The mechanisms at multiple points. Inhibitory coreceptors, 2020;8:e001014. doi:10.1136/ success of these therapies verified that inhib- including programmed cell death 1 (PD-1) and cytotoxic jitc-2020-001014 itory coreceptors serve as critical checkpoints T lymphocyte antigen 4 (CTLA-4), serve as critical checkpoints in restricting immune responses against for immune cells to not attack the tumor Accepted 29 July 2020 self- tissues and tumor cells. Immune checkpoint inhibitors cells as well as self-tissues. However, response that block PD-1 and CTLA-4 pathways significantly rates are typically lower and immune-related improved the outcomes of patients with diverse cancer adverse events (irAEs) are also observed in types and have revolutionized cancer treatment. However, patients administered with immune check- response rates to such therapies are rather limited, and point inhibitors. This is indicative of the immune-rela ted adverse events are also observed in a continued need to decipher the complex substantial patient population, leading to the urgent need biology of inhibitory coreceptors to increase for novel therapeutics with higher efficacy and lower response rates and prevent such unwanted toxicity.
    [Show full text]
  • A Folding Switch Regulates Interleukin 27 Biogenesis and Secretion of Its Α-Subunit As a Cytokine
    A folding switch regulates interleukin 27 biogenesis and secretion of its α-subunit as a cytokine Stephanie I. Müllera,b, Antonie Friedlc, Isabel Aschenbrennera,b, Julia Esser-von Bierenc, Martin Zachariasd, Odile Devergnee,1, and Matthias J. Feigea,b,1 aCenter for Integrated Protein Science, Department of Chemistry, Technical University of Munich, 85748 Garching, Germany; bInstitute for Advanced Study, Technical University of Munich, 85748 Garching, Germany; cCenter of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, 80802 Munich, Germany; dCenter for Integrated Protein Science, Physics Department, Technical University of Munich, 85748 Garching, Germany; and eSorbonne Université, INSERM, CNRS, Centre d’Immunologie et des Maladies Infectieuses, 75 013 Paris, France Edited by John J. O’Shea, NIH, Bethesda, MD, and accepted by Editorial Board Member Tadatsugu Taniguchi December 10, 2018 (received for review October 3, 2018) A common design principle of heteromeric signaling proteins is the by the secretion and biological activity of some isolated α-and use of shared subunits. This allows encoding of complex messages β-subunits (10, 11). A prominent example is IL-27α/p28. Murine IL- while maintaining evolutionary flexibility. How cells regulate and 27α, also designated as IL-30, is secreted in isolation (12) and per- control assembly of such composite signaling proteins remains an forms immunoregulatory roles (13–16). In contrast, no autonomous important open question. An example of particular complexity and secretion of human IL-27α has been reported yet. The molecular biological relevance is the interleukin 12 (IL-12) family. Four func- basis for this difference has remained unclear, but it is likely to have tionally distinct αβ heterodimers are assembled from only five sub- a profound impact on immune system function, since in mice IL-27 units to regulate immune cell function and development.
    [Show full text]
  • Lymphocyte Activation Gene-3 – the Expression and Function in the Immune System
    Lymphocyte Activation Gene-3 – the expression and function in the immune system Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-naturwissenschaftlichen Fakultät der Universität Basel von Malgorzata Kisielow aus Edmonton, Kanada Basel, 2006 Genehmigt von der Philosphisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Antonius Rolink und PD. Dr. Patrick Matthias Basel, den 24 Mai 2005 Prof. Dr. Hans-Jakob Wirz 2 Mojej Mamie Mojemu Tacie 3 TABLE OF CONTENTS ABBREVIATIONS 7 SUMMARY 9 1. INTRODUCTION 11 1.1. The immune system 11 1.1.1. Players of adaptive immunity 12 1.1.1.1. B lymphocytes 12 - B2 B cells 13 - B1 B cells 13 - Marginal zone B cells 14 1.1.1.2. T lymphocytes 14 - αβ T cells 15 Helper T cells 15 Cytotoxic T cells 16 Regulatory T cells 16 NK T cells 17 - γδ T cells 18 1.1.1.3. Antigen Presenting Cells 18 - Denritic cells 19 1.1.1.4. Natural Killer Cells 21 1.1.2. Lymphocyte homeostasis 21 1.1.3. T cell responses 22 1.1.4. T cell-B cell collaboration in B cell responses 24 - Germinal Center reaction 27 1.2. Lymphocyte Activation Gene-3 28 1.2.1. Identification and the predicted structure 28 1.2.2. LAG-3 expression pattern 31 1.2.3. Regulation of Lag-3 expression 33 1.2.4. Suggested function of LAG-3 35 1.2.5. Mode of action of LAG-3 36 1.2.6. LAG-3 and cancer 38 2. THESIS OBJECTIVES 40 3.
    [Show full text]
  • 1 Interleukin 27 Is a Potential Rescue Therapy for Acute Severe Colitis Via Interleukin-10 Dependent, T
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Aberdeen University Research Archive 1 1 Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T 2 cell independent attenuation of colonic mucosal innate immune responses 3 Mairi H McLean1,2, Caroline Andrews1, Miranda L Hanson1, Walter A Baseler1, Miriam R Anver3, 4 Emilee Senkevitch1, Aleksandra K Staniszewska1,2, Christopher Smith1,2, Luke C Davies1, Julie Hixon1, 5 Wenqeng Li1, Wei Shen1, Lothar Steidler4, Scott K Durum1 6 7 1Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, 8 Maryland, 21702, USA; 2School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, 9 Scotland, AB25 2ZD, UK; 3Pathology/Histotechnology Laboratory, Laboratory Animal Sciences 10 Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, 11 Frederick, Maryland, 21702, USA; 4Intrexon Actobiotics N.V., 9052 Zwijnaarde, Belgium 12 Short title; IL-27 attenuates colonic innate immune responses 13 * Correspondence Dr. Scott K Durum 14 National Cancer Institute, Laboratory of Molecular Immunoregulation, Bldg 560, 15 1050 Boyles Street, Frederick, MD 21702-1201 16 Tel: +1-301-846-1545, Fax: +1-301-846-6752 17 Email: [email protected] 18 Conflicts of Interest and Source of Funding 19 Lothar Steidler is a shareholder of Intrexon Corporation and employee of Intrexon Actobiotics N.V. The 20 other authors have declared that no conflict of interest exists. 2 21 This work was supported in part by the Intramural Research Program of the National Institutes of Health, 22 National Cancer Institute, as well as a fellowship funded by Crohn’s and Colitis Foundation of America 23 (MHM) and a grant from the Broad Medical Research Foundation.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]
  • Structural Basis of Sterol Recognition and Nonvesicular Transport by Lipid
    Structural basis of sterol recognition and nonvesicular PNAS PLUS transport by lipid transfer proteins anchored at membrane contact sites Junsen Tonga, Mohammad Kawsar Manika, and Young Jun Ima,1 aCollege of Pharmacy, Chonnam National University, Bukgu, Gwangju, 61186, Republic of Korea Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved December 18, 2017 (received for review November 11, 2017) Membrane contact sites (MCSs) in eukaryotic cells are hotspots for roidogenic acute regulatory protein-related lipid transfer), PITP lipid exchange, which is essential for many biological functions, (phosphatidylinositol/phosphatidylcholine transfer protein), Bet_v1 including regulation of membrane properties and protein trafficking. (major pollen allergen from birch Betula verrucosa), PRELI (pro- Lipid transfer proteins anchored at membrane contact sites (LAMs) teins of relevant evolutionary and lymphoid interest), and LAMs contain sterol-specific lipid transfer domains [StARkin domain (SD)] (LTPs anchored at membrane contact sites) (9). and multiple targeting modules to specific membrane organelles. Membrane contact sites (MCSs) are closely apposed regions in Elucidating the structural mechanisms of targeting and ligand which two organellar membranes are in close proximity, typically recognition by LAMs is important for understanding the interorga- within a distance of 30 nm (7). The ER, a major site of lipid bio- nelle communication and exchange at MCSs. Here, we determined synthesis, makes contact with almost all types of subcellular or- the crystal structures of the yeast Lam6 pleckstrin homology (PH)-like ganelles (10). Oxysterol-binding proteins, which are conserved domain and the SDs of Lam2 and Lam4 in the apo form and in from yeast to humans, are suggested to have a role in the di- complex with ergosterol.
    [Show full text]